A delayed clinical trial actually boosted Bristol Myers Squibb's stock. Here's why.

Bristol Myers' stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer's treatment, even though the outcome of a late-stage trial has been delayed. ...